Nikon Corporation Healthcare Business Unit | Asia, Oceania & Middle East
- en Change Region
- Global Site
January 2014
Anti-cancer NK-92 lymphocytes are promising for application in immunotherapies. This application note explores a comprehensive workflow for producing clinical-grade NK-92 cells, using Nikon’s BioStation CT to monitor NK-92 phenotype and potency.